Free Trial

Leeward Investments LLC MA Acquires 33,588 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

QuidelOrtho logo with Medical background

Leeward Investments LLC MA increased its position in shares of QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 17.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 229,847 shares of the company's stock after purchasing an additional 33,588 shares during the quarter. Leeward Investments LLC MA owned 0.34% of QuidelOrtho worth $10,481,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of QDEL. Fifth Third Bancorp lifted its position in shares of QuidelOrtho by 907.3% during the 2nd quarter. Fifth Third Bancorp now owns 826 shares of the company's stock worth $27,000 after buying an additional 744 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of QuidelOrtho by 27.0% in the 2nd quarter. GAMMA Investing LLC now owns 1,778 shares of the company's stock valued at $59,000 after purchasing an additional 378 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of QuidelOrtho during the 1st quarter valued at approximately $86,000. Innealta Capital LLC acquired a new position in QuidelOrtho during the 2nd quarter worth approximately $102,000. Finally, Quest Partners LLC boosted its position in QuidelOrtho by 17,095.0% in the second quarter. Quest Partners LLC now owns 3,439 shares of the company's stock valued at $114,000 after buying an additional 3,419 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.

QuidelOrtho Stock Down 2.8 %

NASDAQ:QDEL traded down $1.11 on Thursday, hitting $38.85. The stock had a trading volume of 704,619 shares, compared to its average volume of 963,316. The company has a market cap of $2.61 billion, a PE ratio of -1.40 and a beta of 0.12. QuidelOrtho Co. has a 52 week low of $29.74 and a 52 week high of $75.86. The business's fifty day moving average is $42.24 and its 200 day moving average is $40.42. The company has a quick ratio of 0.79, a current ratio of 1.44 and a debt-to-equity ratio of 0.70.

Analyst Ratings Changes

Several equities analysts have commented on QDEL shares. UBS Group assumed coverage on QuidelOrtho in a research report on Thursday, September 19th. They issued a "neutral" rating and a $50.00 target price for the company. Craig Hallum raised shares of QuidelOrtho from a "hold" rating to a "buy" rating and boosted their target price for the stock from $40.00 to $57.00 in a report on Thursday, September 5th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price target on shares of QuidelOrtho in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $58.83.

Get Our Latest Report on QuidelOrtho

About QuidelOrtho

(Free Report)

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.

Recommended Stories

Institutional Ownership by Quarter for QuidelOrtho (NASDAQ:QDEL)

Should you invest $1,000 in QuidelOrtho right now?

Before you consider QuidelOrtho, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and QuidelOrtho wasn't on the list.

While QuidelOrtho currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines